|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
BRCA2 carriers had an SIR of 4.45 (95% confidence interval [CI] 2.99-6.61) and absolute PCa risk of 27% (95% CI 17-41%) and 60% (95% CI 43-78%) by ages 75 and 85 yr, respectively.
|
31495749 |
2020 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive PCa.
|
31723001 |
2020 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our findings provide a rationale for the future use of immune oncological approaches in BRCA2-mutated prostate cancer and may encourage efforts to target immunosuppressive T-cell populations to prime tumors for immunotherapy.
|
31549213 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Subsequent BRCA2 mutation studies have shown an association with PCa risk and mortality.
|
30900310 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
<i>Conclusions</i>: Our results provide a pre-clinical rationale for the use of 6-TG in the treatment of BRCA2-deficient castration-resistant prostate cancers, and of certain 6-TG analogues for treatment of BRCA2-proficient prostate cancers.
|
31284411 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
Molecular testing determined that his t-NEPC tumor (but not his original adenocarcinoma) harbored complete copy number loss of BRCA2, as well as copy number loss of another HR gene - ataxia telangiectasia, mutated (ATM).
|
31565603 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
We developed a 3-color FISH assay to detect genomic deletions of BRCA2 and RB1 in prostate cancer cells and patient-derived mCRPC organoids.
|
31796516 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutation increases the risks of aggressive PCa and other cancer types in Japanese males.
|
31631483 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Significantly, pathogenic BRCA2 mutations in men with localized early stage PCa increased the risk of distant metastasis.
|
30542053 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
BRCA2 and Other DDR Genes in Prostate Cancer.
|
30871108 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
Survival and cell-cycle alterations were performed after drug treatments in isogenic DT40, DLD1, and OVCAR cell lines with BRCA1, BRCA2, or PALB2 deficiencies and in organoids cultured from prostate cancer patient-derived xenografts with BRCA2 loss.
|
31409613 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Association with PCa risk was statistically significant for variants in BRCA2 (P < 0.001, OR = 5.65, 95% CI = 3.55-9.32), HOXB13 (P < 0.001, OR = 4.73, 95% CI = 2.84-8.19), and ATM (P < 0.001, OR = 2.86, 95% CI = 1.63-5.15).
|
31214711 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception.
|
29802810 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The influence of BRCA2 mutation on localized prostate cancer.
|
30808988 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations.
|
31537406 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
SPA-induced DSBs were accentuated in BRCA2-deficient PCs, and combining SPA with PARP or DNA-PKcs inhibition further repressed growth.
|
31310591 |
2019 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group.
|
29661970 |
2018 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, we are the first to report the germline BRCA2 mutation c.4211C>G (p.Ser1404Ter) in prostate cancer.
|
29580149 |
2018 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
As breast and prostate cancer share genetic risk factors, including rare, high-risk mutations (eg, in BRCA2), we hypothesized that some of these heritable methylation marks might also be associated with the risk of prostate cancer.
|
30133758 |
2018 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Protein-truncating mutations in BRCA2 and BRIP1 were discovered in African American men diagnosed with early-onset prostate cancer.
|
29356034 |
2018 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This dysregulation is enriched in BRCA2-mutant PCa harbouring intraductal carcinoma (IDC).
|
28067867 |
2017 |
|
Malignant neoplasm of prostate
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Mutations in BRCA2 and taxane resistance in prostate cancer.
|
28676659 |
2017 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
In addition, BRCA2 modulation may be a strategy to partially reverse docetaxel resistance in prostate cancer.
|
28928839 |
2017 |
|
Malignant neoplasm of prostate
|
0.900 |
Biomarker
|
disease |
BEFREE |
Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer.
|
28623070 |
2017 |